CN107810003B - 包含瓦伦托宁的透皮治疗系统及其作为药物的应用 - Google Patents

包含瓦伦托宁的透皮治疗系统及其作为药物的应用 Download PDF

Info

Publication number
CN107810003B
CN107810003B CN201680019543.5A CN201680019543A CN107810003B CN 107810003 B CN107810003 B CN 107810003B CN 201680019543 A CN201680019543 A CN 201680019543A CN 107810003 B CN107810003 B CN 107810003B
Authority
CN
China
Prior art keywords
vlt
patch
melatonin
transdermal therapeutic
therapeutic system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201680019543.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN107810003A (zh
Inventor
珍-伯纳德·富尔蒂兰
玛丽安娜·富尔蒂兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Soeur Josefa Menendez
Original Assignee
Soeur Josefa Menendez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soeur Josefa Menendez filed Critical Soeur Josefa Menendez
Publication of CN107810003A publication Critical patent/CN107810003A/zh
Application granted granted Critical
Publication of CN107810003B publication Critical patent/CN107810003B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680019543.5A 2015-02-04 2016-02-04 包含瓦伦托宁的透皮治疗系统及其作为药物的应用 Expired - Fee Related CN107810003B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305161 2015-02-04
EP15305161.0 2015-02-04
PCT/EP2016/052376 WO2016124688A1 (fr) 2015-02-04 2016-02-04 Systeme therapeutique transdermique contenant de la valentonine et son utilisation comme medicament

Publications (2)

Publication Number Publication Date
CN107810003A CN107810003A (zh) 2018-03-16
CN107810003B true CN107810003B (zh) 2022-05-03

Family

ID=52573642

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680019543.5A Expired - Fee Related CN107810003B (zh) 2015-02-04 2016-02-04 包含瓦伦托宁的透皮治疗系统及其作为药物的应用

Country Status (9)

Country Link
US (1) US10744122B2 (https=)
EP (1) EP3253378B1 (https=)
JP (1) JP6785779B2 (https=)
KR (1) KR102361801B1 (https=)
CN (1) CN107810003B (https=)
CA (1) CA2975985A1 (https=)
ES (1) ES2738633T3 (https=)
HU (1) HUE045679T2 (https=)
WO (1) WO2016124688A1 (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503202A (ja) * 1991-10-18 1995-04-06 アイティーティー・オートモーティブ・ヨーロップ・ゲーエムベーハー アンチロック制御付液圧ブレーキシステム
CN1161039A (zh) * 1994-09-14 1997-10-01 西玛夫公司 新型褪黑激素拮抗药、其制备方法及其药品用途
EP1214944A1 (en) * 1999-08-20 2002-06-19 Takeda Chemical Industries, Ltd. Percutaneous absorption agents
CN1787820A (zh) * 2003-04-29 2006-06-14 纽里姆药品(1991)有限公司 提高认知和记忆的组合物
WO2007101863A1 (fr) * 2006-03-08 2007-09-13 Macef Association therapeutique d'un antagoniste du recepteur 5ht2 et d'activateur du recepteur 5ht2
WO2008101824A1 (fr) * 2007-02-08 2008-08-28 Fourtillan Derives des imidazo[1',5':1,6] pyrido[3,4-b]indoles et leur utilisation en therapeutique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116036A1 (en) * 1991-10-18 1993-04-29 F. Eugene Yates Device for the transdermal administration of melatonin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503202A (ja) * 1991-10-18 1995-04-06 アイティーティー・オートモーティブ・ヨーロップ・ゲーエムベーハー アンチロック制御付液圧ブレーキシステム
CN1161039A (zh) * 1994-09-14 1997-10-01 西玛夫公司 新型褪黑激素拮抗药、其制备方法及其药品用途
EP1214944A1 (en) * 1999-08-20 2002-06-19 Takeda Chemical Industries, Ltd. Percutaneous absorption agents
CN1787820A (zh) * 2003-04-29 2006-06-14 纽里姆药品(1991)有限公司 提高认知和记忆的组合物
WO2007101863A1 (fr) * 2006-03-08 2007-09-13 Macef Association therapeutique d'un antagoniste du recepteur 5ht2 et d'activateur du recepteur 5ht2
WO2008101824A1 (fr) * 2007-02-08 2008-08-28 Fourtillan Derives des imidazo[1',5':1,6] pyrido[3,4-b]indoles et leur utilisation en therapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Formulation and In Vitro Evaluation of Transdermal Patches of Melatonin;N. Kanikkannan等;《DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY》;20041103;第30卷(第2期);摘要第1-4行 *

Also Published As

Publication number Publication date
HUE045679T2 (hu) 2020-01-28
KR20180004100A (ko) 2018-01-10
WO2016124688A1 (fr) 2016-08-11
JP6785779B2 (ja) 2020-11-18
KR102361801B1 (ko) 2022-02-10
JP2018507850A (ja) 2018-03-22
US10744122B2 (en) 2020-08-18
CA2975985A1 (fr) 2016-08-11
CN107810003A (zh) 2018-03-16
ES2738633T3 (es) 2020-01-24
EP3253378B1 (fr) 2019-05-08
EP3253378A1 (fr) 2017-12-13
US20180000796A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
Fujita et al. Nutrient signalling in the regulation of human muscle protein synthesis
Kersanté et al. A functional role for both γ‐aminobutyric acid (GABA) transporter‐1 and GABA transporter‐3 in the modulation of extracellular GABA and GABAergic tonic conductances in the rat hippocampus
Van de Graaf et al. Up to date with human thyroglobulin
Wallace et al. Computer-controlled lidocaine infusion for the evaluation of neuropathic pain after peripheral nerve injury
Cagetti et al. Chronic intermittent ethanol (CIE) administration in rats decreases levels of neurosteroids in hippocampus, accompanied by altered behavioral responses to neurosteroids and memory function
Tao et al. Influence of inhibitory and excitatory inputs on serotonin efflux differs in the dorsal and median raphe nuclei
Takasu et al. Spinal hyperpolarization-activated cyclic nucleotide-gated cation channels at primary afferent terminals contribute to chronic pain
Garry et al. Evaluation of the efficacy of a bioerodible bupivacaine polymer system on antinociception and inflammatory mediator release
Cairns et al. Systemic administration of monosodium glutamate elevates intramuscular glutamate levels and sensitizes rat masseter muscle afferent fibers
Mercolini et al. HPLC analysis of the novel antidepressant duloxetine in human plasma after an original solid-phase extraction procedure
Xie et al. Development and validation of a sensitive LC–MS/MS method for the determination of d-serine in human plasma
Collier et al. Development and application of a validated HPLC method for the analysis of dissolution samples of levothyroxine sodium drug products
Meng et al. Effects of endogenous melatonin on glutamate and GABA rhythms in the striatum of unilateral 6-hydroxydopamine-lesioned rats
West et al. Intrastriatal infusion of (±)‐S‐nitroso‐N‐acetylpenicillamine releases vesicular dopamine via an ionotropic glutamate receptor‐mediated mechanism: an in vivo microdialysis study in chloral hydrate‐anesthetized rats
Shen et al. Nicotinamide mononucleotide (NMN) and NMN-rich product supplementation alleviate p-chlorophenylalanine-induced sleep disorders
Dopico et al. Glycine release in the substantia nigra: interaction with glutamate and GABA
CN107810003B (zh) 包含瓦伦托宁的透皮治疗系统及其作为药物的应用
Erhardt et al. Nicotine‐induced excitation of locus coeruleus neurons is blocked by elevated levels of endogenous kynurenic acid
Lotsch et al. Effects of azapropazone on pain‐related brain activity in human subjects.
Siddiqui et al. Development and validation of stability-indicating HPLC method for the simultaneous determination of paracetamol, tizanidine, and diclofenac in pharmaceuticals and human serum
Zlotnik et al. β2 adrenergic-mediated reduction of blood glutamate levels and improved neurological outcome after traumatic brain injury in rats
Cenani et al. Pharmacokinetics and pharmacodynamics of intravenous romifidine and propranolol administered alone or in combination for equine sedation
Dingemanse et al. Integrated pharmacokinetics and pharmacodynamics of Ro 48–6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects
Yang et al. Release property study on the novel divalproex sodium enteric-coated capsules
Mayer et al. Microperfusion of 3-MPA into the brain augments GABA

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220503

CF01 Termination of patent right due to non-payment of annual fee